SciSparc subsidiary NeuroThera secures drug batch release for Phase IIb Tourette trial
SPRC•SciSparc subsidiary NeuroThera Labs secured European batch release certification for SCI-110, enabling shipments for its FDA-approved Phase IIb Tourette syndrome trial. All three study sites completed initiation activities, and shipments are expected in the near term.
1. Trial preparations advance
NeuroThera Labs secured European batch release certification for SCI-110, allowing shipments for the Phase IIb trial in adults with Tourette syndrome. All three study sites completed initiation activities, and the study will evaluate SCI-110’s efficacy, safety and tolerability.
